Patrick Harrison Carroll, serving as the Chief Medical Officer for Hims & Hers Health, Inc. (NASDAQ:HIMS), completed a direct sale of 23,726 shares of the company's Class A Common Stock on June 18, 2026. The transaction carried a total value of $830,410, with the shares transacted at a price of $35.00 per share.
Following this divestment, Mr. Carroll's direct holdings in Hims & Hers Health, Inc. Class A Common Stock stand at 181,861 shares. The Form 4 filing, which provides the official details of this transaction, was made publicly available on June 23, 2026.
Executive share sales are closely monitored by market participants as they can signal internal perspectives on valuation and future prospects. In this instance, the transaction represents a portion of Mr. Carroll's holdings rather than a complete exit, leaving him with a substantial remaining position.
Recent corporate developments at Hims & Hers Health include analyst coverage adjustments. Barclays raised its price target for Hims & Hers Health stock to $39, up from $29, while maintaining an Overweight rating. This adjustment follows the company's partnership with Novo Nordisk, which contributed to a notable increase in website traffic.
Concurrently, Leerink reiterated a Market Perform rating with a $25 price target. This outlook comes as the company prepares for a regulatory meeting concerning compounded peptides, a key area of focus for the digital health platform.
Corporate governance also saw updates during the company's annual meeting. Shareholders elected nine directors, including Andrew Dudum and Deborah Autor, to serve terms extending until 2027. Additionally, Hims & Hers Health appointed Dr. Anant Vinjamoori as Chief Medical Officer. Dr. Vinjamoori will oversee clinical guidance across various health categories, marking a strategic move to strengthen leadership within the organization.
These developments collectively highlight the company's ongoing efforts toward strategic growth and expansion. The combination of analyst activity, partnership developments, and leadership appointments underscores the dynamic nature of Hims & Hers Health's current operational phase.